|Day Low/High||0.28 / 0.32|
|52 Wk Low/High||0.14 / 11.65|
Investors in Insys Therapeutics Inc saw new options begin trading this week, for the April 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new April 15th contracts and identified one put and one call contract of particular interest.
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased...
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CAG, CCBG, CREE, ESRT, MLNX, MPX, PDCO, TMUS, VSAT, WMT Downgrades: BKU, FFIN, INSY, IPXL, LM, MGLN, MRC, THC Initiations: ONDK, VLRS Read on to get TheStreet Quant Ratings' detailed report:
Rosen Law Firm, a global investor rights law firm, reminds purchasers of INSYS Therapeutics, Inc.
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of investors who purchased or otherwise acquired the common stock of Insys Therapeutics, Inc.
Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against INSYS Therapeutics, Inc.
Trade-Ideas LLC identified Insys Therapeutics (INSY) as a weak on high relative volume candidate
These five candidates for Worst Biopharma CEO of 2015 have bathed in the muck of mediocrity long enough to warrant your scorn.
Don't be a lemming! The investment herd is punishing these three stocks, but a rational analysis shows that they're all undervalued growth opportunities for 2016.
Trade-Ideas LLC identified Insys Therapeutics (INSY) as a "perilous reversal" (up big yesterday but down big today) candidate
Live Webcast to Begin at 8:30 a.m. EST
Shares of Diplomat Pharmacy and pharmacy benefit manager Express Scripts have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant and others...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.